Search

Eli Lilly's July 2026 TRIUMPH Phase 3 topline showed retatrutide produced up to 28.7% mean weight loss at 68 weeks in obesity patients without diabetes, sending ripples through the peptide supply chain.

Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.

ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.